Global Systemic Juvenile Idiopathic Arthritis Market - 2023-2030

Overview

Global Systemic Juvenile Idiopathic Arthritis Market reached US$ 0.87 billion in 2022 and is expected to reach US$ 1.19 billion by 2030.

Juvenile idiopathic arthritis (JIA) is a highly common type of arthritis in kids and teens. Around 10% to 20% of juveniles with JIA carry an infrequent and severe subtype called systemic juvenile idiopathic arthritis (SJIA). "Systemic" indicates that it may impact not just the joints but even additional parts of the body, such as the liver, lungs, and heart. SJIA, often referred to as Still's condition, can transpire at any moment in childhood.

Despite its most typical beginning at approximately two years of age, the males and females are equally impacted. SJIA also varies among different subtypes in that it is exclusively regarded as an autoinflammatory instead of an autoimmune condition. SJIA is additionally extreme and can be more difficult to interpret and treat compared to other types of juvenile idiopathic arthritis. It is a lifelong condition for numerous patients and can persist into adulthood.

The increasing authorizations, positive outcomes from research activities, market developments including mergers, acquisitions, products introductions, growing awareness among other factors are expected to boost the global systemic juvenile idiopathic arthritis market growth in the forecast period. Further, the growing cases and research fundings are also expected to contribute to the global market growth in the forecast period.

Dynamics

Increasing Product Approvals and Positive Research Outcomes

The increasing product approvals and positive outcomes from distinct clinical investigations are expected to boost the global market growth in the forecast period. For instnace, in January 2023, the National Medical Products Administration (NMPA) of China authorized the Bio-Thera Solution's biosimilar of Actemra (tocilizumab), BAT1806, a recombinant humanized monoclonal antibody designed to target interleukin-6 receptor (IL-6R). It has been authorized for the treatment of cytokine release syndrome (CRS), rheumatoid arthritis (RA), and systemic juvenile idiopathic arthritis (sJIA). The FDA and EMA have accepted the marketing authorization application for BAT1806/BIIB800.

Moreover, according to a recent study Emapalumab, a completely human anti-interferon-γ (IFNγ), showed effectiveness for causing remission of macrophage activation syndrome (MAS) secondary to systemic juvenile idiopathic arthritis (sJIA) or adult-onset Still's disease (AOSD) in individuals who did not obtain effect with usual care with high-dose glucocorticoids, with or without anakinra (Kineret; Sobi) and/or cyclosporin. Emapalumab was investigated in a phase 2, open-label, single-arm trial (NCT03311854) that was executed at 5 locations in France, Italy, Spain, the United Kingdom, and the United States.

Increasing Efforts from Distinct Associations

Increasing Efforts from Distinct Associations to enhance the overall management of Juvenile Idiopathic Arthritis (JIA) and associated conditions. For instance, in March 2023, the Canadian Rheumatology Association (CRA) publicized policies for the screening, monitoring, and treatment of juvenile idiopathic arthritis (JIA)-associated uveitis. Investigations assessing systemic therapies in JIA-associated uveitis are restricted in spite of a uniform therapy procedure and regulatory body clearance for new treatments.

The American College of Rheumatology (ACR)/Arthritis Foundation (AF) policies deliver possibilities for education and lobbying to regional, provincial, and federal regulatory agents and payers to sufficiently access breakthrough treatments. The availability of expert agreement norms for monitoring and controlling JIA-associated uveitis in Canada is expected to assist in normalizing the most elevated standard of care across the nation.

Moreover, at the recent American College of Rheumatology (ACR) Convergence 2021 summit, there was a fascinating discussion targeting adult rheumatologists on how to handle adult patients with juvenile idiopathic arthritis (JIA). Further, the National Institute for Health and Care Excellence, NICE in September 2021, issued a final draft recommendation that guides tofacitinib (also known as Xeljanz and made by Pfizer) as a choice for treating active polyarticular juvenile arthritis and juvenile psoriatic arthritis in individuals 2 years and older.

High Treatment Cost of Systemic Juvenile Idiopathic Arthritis

The high treatment cost of Systemic Juvenile Idiopathic Arthritis is expected to hamper the global market growth in the forecast period. For instnace, the monetary expense of JIA can be high, in particular, the yearly total for managing juveniles with JIA in the U.S. can vary anywhere from $300 to nearly $45,000, according to a 2021 study in Pediatric Rheumatology. Moreover, the biological medication, Novartis's Ilaris, small vial expenses in-between from $16,000 to $37,000 for each dose relying on insurance coverage.

Further, the entire yearly expenses for the family of an individual with juvenile idiopathic arthritis are considerable, varying from $1,122 to $44,832, with the most elevated dollar payments spent on medication and medical appointments, according to data. These high costs for Systemic Juvenile Idiopathic Arthritis are leaving behind a mjority of impacted individuals hampering the global market growth.

Low Prevalence of the Disorder

The low prevalence of systemic juvenile idiopathic arthritis is expected to hamper the global market growth during the forecast period. For instance, the annual incidence of JIA in New Zealand is 5.1/100,000 and is categorized according to the International League of Associations for Rheumatology (ILAR) standards of which Oligoarticular with 47% of cases and polyarticular with 26% of cases making them the most typical subtypes represented by arthritis in 4 or less and 5 or more joints respectively within the foremost 6 months of interpretation. Less expected subtypes included enthesitis-related arthritis with 15% of cases, systemic JIA accounting for 8% of cases, and psoriatic arthritis with 3% of cases.

While the presence of JIA is quite increased in European children with 7.2 per 100,000 individuals, Maori and Pacific Island children have significantly better potential to provide insufficient predictive features corresponding to European children including cervical involvement, erosive transformations, common area narrowing, and rheumatoid characteristic positive disorder. In Europe, it is estimated that less than one child per 100,000 develops SJIA every year. It is estimated that between 5 and 15 individuals in every 100,000 currently have SJIA, impacting boys and girls equally worldwide.

Segment Analysis

The global systemic juvenile idiopathic arthritis market is segmented based on treatment type, route of administration, age group, end-user and region.

Biologics Treatment Type Expected to Dominate Market

Owing to the increasing market developments in the biologics segment, it is expected to dominate the global market in the forecast period. For instance, in August 2023, CVS Health, introduced Cordavis, a fully held associate that is expected to operate immediately with manufactories to market and/or co-produce biosimilar developments for the U.S. pharmaceutical demand. The Cordavis developments are expected to be FDA-authorized, high-grade, and comfortable for individuals to utilize and are expected to aid in ensuring a constant long-term reserve of inexpensive biosimilars.

As the U.S. pharmaceutical atmosphere continues to grow, biosimilars describe one of the most significant prospects for lowering drug expenses for employers and clients, via Cordavis, CVS Health plans to design a portfolio of developments that it intends to facilitate wider access to biosimilars in the U.S. producing better competition that pushes down expenses while promoting asset in prospective products. The biosimilar market in the U.S. is anticipated to increase from less than $10 billion in 2022 to over $100 billion by 2029.

As its foremost development, Cordavis has acquired Sandoz to market and brought to market Hyrimoz (adalimumab-adaz), a biosimilar for Humira suggested for lowering symptoms and manifestations of moderately to severely active polyarticular JIA in individuals of age 2 years and older. HYRIMOZ can be utilized unaided or in blend with methotrexate in the first quarter of 2024 under a Cordavis private brand. The list expense of Cordavis Hyrimoz will be over 80% lower than the present list cost of Humira.

Geographical Penetration

Increasing Cases of Systemic Juvenile Idiopathic Arthritis

The growing cases of systemic juvenile idiopathic arthritis and distinct government organizations' research funding are expected to boost the North America market, holding the majority of the global market share. For instance, roughly 6,200 (0.10%) Canadians aged 15 years and younger live with diagnosed JIA and about 1,000 (17.1 per 100,000 persons per year) were recently diagnosed in 2016-2017. The preponderance and cases of interpreted JIA typically grow with age and are additionally raised in females (0.13% and 21.1 per 100,000 individuals per year, respectively) corresponding to males (0.08% and 13.4 per 100,000 persons per annum, respectively).

Moreover, in July 2022, the Arthritis Foundation in collaboration with the Childhood Arthritis and Rheumatology Research Alliance (CARRA), supported the recognition of eight CARRA researchers adding to $1,122,755 to perform research desired to enhancing developments in childhood rheumatic disorders, including juvenile idiopathic arthritis, the most typical form of arthritis analyzed in juveniles. The Arthritis Foundation assesses there are almost 300,000 children and teens with arthritis in the United States. Childhood-onset rheumatic disorders enclose different sorts of arthritis and other rheumatic and inflammatory disorders that evolve in children and teens.

COVID-19 Impact Analysis

During the COVID-19 pandemic, elective and routine examinations and operations were postponed or discontinued because of redirecting aids to additional emergent therapy for extremely sick individuals and to avert the spread and contraction of COVID-19. Further, the workforce was pulled narrow, and healthcare structures witnessed growing turnover rates for full-time and agreement workers, which pushed the system and decreased the capacity to deliver clinical assistance.

Since more beds in wards and intensive care units were assigned to COVID-19 patients, considerable surgical divisions registered a reduction in the number of patient visits. The imposition of lockdown as a strategy to flatten the curve of COVID-19 patients also stalled the management of these patients. However, currently majority of healthcare departments have recovered and gained the number of patient vesting's to a standard value.

By Treatment Type

• Drug Treatment
  • Anti-inflammatories (NSAIDS)
  • Tumor Necrosis Factor (TNF) Blockers
  • Muscle Relaxants
  • Immune Suppressants Drugs
  • Disease Modifying Antirheumatic Drugs
  • Others

• Biologics
• Other

By Route of Administration

• Oral
• Injectables
• Other

• Age Group
  • Infants
  • Childrens
  • Adolescents

By End-User

• Hospitals
• Specialty Clinics
• Academic Research Centers
• Others

By Region

• North America
  • U.S.
  • Canada
  • Mexico

• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Rest of Europe

• South America
  • Brazil
  • Argentina
  • Rest of South America

• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific

• Middle East and Africa

Key Developments

• In August 2023, CVS Health introduced Cordavis, an entirely owned that is expected to function directly with manufactories to commercialize and/or co-produce biosimilar developments for the U.S. market.
• In June 2022, Baricitinib (Olumiant), a Janus kinase (JAK) inhibitor, greatly raised the time to condition flare and lowered the frequency of flares in patients with juvenile idiopathic arthritis (JIA), according to the outcomes of a phase 3, placebo-controlled investigation.

Competitive Landscape

The major global players in the market include: Novartis AG, Hoffmann-La Roche Ltd, Takeda Pharmaceutical Company Limited, Bristol - Myers Squibb Company, Cadila Healthcare Ltd., Genetech, Inc., LATAM Pharma, Alteogen Inc., Johnson & Johnson, and Momenta Pharmaceuticals, Inc. among others.

Why Purchase the Report?

• To visualize the global systemic juvenile idiopathic arthritis market segmentation based on treatment type, route of administration, age group, end-user, and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of systemic juvenile idiopathic arthritis market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key product of all the major players.

The global systemic juvenile idiopathic arthritis market report would provide approximately 61 tables, 58 figures and 186 Pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies